Zevra Therapeutics, Inc. ZVRA R2KR3KPHARMA
Company Overview
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Generates a return on equity of 34.8%, reflecting efficient use of shareholder capital.
Revenue has grown at a 52.7% CAGR over the past five years.
Trades at a P/E of 10.6, below the sector median of 25.4.
Maintains a net profit margin of 42.8%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $106.47M (+350.9% YoY); net profit $83.23M.
- Trailing 12 Months Year-on-year growth — revenue +53.3%, earnings -88.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 52.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 52.66% |
| 1 Year: | 53.30% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -88.40% |
Stock Price Performance
| 1 Year: | +4.03% |
| 6 Months: | -2.68% |
| 3 Months: | +1.03% |
| 1 Month: | -12.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.30 · Neutral
P/E of 10.55 is below the sector median of 25.45 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 34.8%.
- Excellent profit margin of 42.8%.
- Compounding revenue at 52.7% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 33.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ZVRA Zevra Therapeutics, Inc. R2KR3KPHARMA | 9.81 | 10.55 | $582.55M | 0.00% | -1.72% | 34.80% | 52.66% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.40M | 25.88M | 26.06M | 34.12M | 36.22M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.34M | 12.38M | 1.24M | 1.52M | 1.90M | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.06M | 13.50M | 24.82M | 32.60M | 34.32M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.42M | 25.83M | 20.68M | 23.29M | 25.49M | - |
| Operating Income | -7.49M | -3.10M | -5.96M | -6.48M | -7.28M | -6.97M | -9.28M | -10.40M | -10.84M | -7.38M | -8.22M | -9.61M | -8.15M | -14.77M | -13.91M | -17.96M | -11.37M | -7.79M | 3.23M | -3.77M | 2.59M | -1.21M | 6.96M | 5.83M | -2.22M | -1.86M | -24.77M | -6.63M | -12.83M | -6.25M | -15.36M | -20.49M | -23.80M | -27.31M | -5.36M | -12.33M | 4.14M | 9.31M | 8.83M | 16.78M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.70M | 80.57M | 1.47M | 14.98M | 46.88M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.97M | 2.01M | 2.05M | 1.95M | 1.71M | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.92M | 76.91M | -977.00K | 12.67M | 44.80M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.18M | 2.20M | -433.00K | 501.00K | 6.91M | - |
| Net Income | -11.84M | -5.97M | -29.74M | -9.74M | -9.20M | -2.93M | 9.77M | -13.41M | -9.94M | -16.32M | -6.52M | -9.98M | -10.57M | -26.22M | -9.99M | -15.07M | -12.29M | -9.26M | 3.06M | -5.75M | 859.00K | -3.01M | -10.30M | 6.20M | -1.76M | -1.86M | -24.04M | -6.62M | -13.22M | -2.57M | -10.37M | -16.62M | -19.93M | -33.23M | -3.10M | 74.71M | -544.00K | 12.16M | 37.89M | 8.75M |
| Diluted EPS | - | -2.50 | -2.45 | -0.68 | -0.64 | -0.20 | -0.58 | -0.92 | -0.68 | -1.11 | -0.44 | -0.68 | -0.72 | - | -0.91 | -0.94 | - | -0.33 | 0.06 | -1.92 | 0.21 | -0.68 | -2.49 | -0.40 | -0.06 | - | - | - | - | - | - | - | -0.48 | -0.69 | -0.06 | 1.21 | -0.01 | - | 0.60 | 0.14 |
| R&D Expense | 5.91M | 2.12M | 2.77M | 4.33M | 4.72M | 3.23M | 4.99M | 4.29M | 7.96M | 4.11M | 4.65M | 6.29M | 5.54M | 11.64M | 10.49M | 13.33M | 8.53M | 4.80M | 3.62M | 2.13M | 1.95M | 1.71M | 2.27M | 2.85M | 2.24M | 3.08M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | - | - | 0 | 12.84M | 13.29M | - | 10.16M | 27.46M | 23.61M | 106.47M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 222.00K | 2.17M | 7.42M | 16.48M |
| Gross Profit | - | - | - | - | - | - | - | - | - | 9.94M | 25.29M | 16.20M | 89.99M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 34.84M | 74.89M | 103.20M | 94.22M |
| Operating Income | -4.72M | -16.44M | -22.81M | -37.48M | -33.37M | -55.90M | -20.34M | -5.61M | - | -24.90M | -49.60M | -87.00M | -4.23M |
| EBITDA | - | - | - | - | - | - | - | - | - | -25.53M | -43.54M | -76.40M | 98.71M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 335.00K | 1.50M | 7.35M | 7.98M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -26.80M | -46.05M | -90.14M | 86.68M |
| Tax Provision | - | - | - | - | - | - | - | - | - | -33.00K | 0 | 15.37M | 3.45M |
| Net Income | -5.23M | -24.45M | -54.66M | -16.52M | -43.39M | -56.47M | -24.52M | -12.76M | - | -26.77M | -46.05M | -105.51M | 83.23M |
| Diluted EPS | - | - | - | - | - | - | - | -3.21 | - | -1.20 | -1.30 | -2.28 | 1.35 |
| R&D Expense | 3.37M | 11.92M | 13.93M | 20.47M | 20.59M | 41.76M | 19.41M | 8.84M | 10.16M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Sep 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 13.71M | 54.59M | 84.89M | 52.46M | 26.75M | 10.51M | 11.21M | - | 115.34M | - | 172.33M | 178.13M | 284.73M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 92.83M | - | 86.94M | 86.03M | 223.01M |
| Cash & Equivalents | 2.54M | 1.97M | 10.26M | 32.32M | 16.76M | 10.87M | 18.41M | 3.22M | 4.21M | - | 65.47M | - | 43.05M | 33.78M | 62.41M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 1.97M | 1.74M |
| Receivables | - | - | - | - | - | - | - | - | - | - | 7.18M | - | 16.12M | 4.01M | 9.88M |
| Total Liabilities | - | - | 38.02M | 64.71M | 103.58M | 109.97M | 93.31M | 84.96M | 77.62M | - | 40.22M | - | 110.46M | 138.46M | 130.07M |
| Current Liabilities | - | - | 3.94M | 8.34M | 6.64M | 11.51M | 12.00M | 5.43M | 7.54M | - | 12.02M | - | 73.72M | 34.06M | 39.28M |
| Long Term Debt | - | - | - | - | - | 92.73M | 81.44M | 77.34M | 67.66M | - | 12.80M | - | 5.07M | 59.50M | 61.93M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 14.12M | - | 43.77M | 60.30M | 63.21M |
| Total Equity | -19.18M | -24.27M | -48.51M | -10.12M | -18.70M | -57.52M | -66.57M | -74.46M | -66.41M | - | 75.12M | 61.52M | 61.86M | 39.67M | 154.66M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 35.45M | - | 43.11M | 55.25M | 58.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -20.27M | -29.77M | -33.10M | -54.20M | -23.74M | -1.94M | - | -18.72M | -33.53M | -69.67M | -1.60M |
| Investing Cash Flow | - | - | -19.14M | -45.85M | 27.41M | 33.33M | 3.23M | -33.00K | - | -36.72M | -17.39M | -22.16M | 18.13M |
| Financing Cash Flow | - | - | 61.47M | 61.16M | -203.00K | 28.02M | 4.94M | 2.74M | - | 8.35M | 28.46M | 82.11M | 12.06M |
| Capital Expenditure | -51.00K | -47.00K | -135.00K | -643.00K | -181.00K | -21.00K | -26.00K | -33.00K | -102.00K | -93.00K | -296.00K | - | -835.00K |
| Free Cash Flow | - | - | -20.40M | -30.41M | -33.28M | -54.22M | -23.76M | -1.97M | - | -18.81M | -33.83M | -69.67M | -2.43M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | -47.08M | -22.46M | -9.72M | 28.59M |
| Share Buybacks | - | - | - | - | - | - | - | 0 | 2.81M | 4.72M | 3.45M | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 97.8% | 92.1% | 68.6% | 84.5% |
| Operating Margin % | - | - | - | - | - | - | -158.4% | -42.2% | - | -245.1% | -180.6% | -368.5% | -4.0% |
| Net Margin % | - | - | - | - | - | - | -191.0% | -96.0% | - | -263.5% | -167.7% | -446.9% | 78.2% |
| ROE % | 21.5% | 50.4% | 540.1% | 88.3% | 75.4% | 84.8% | 32.9% | 19.2% | - | -35.6% | -74.4% | -266.0% | 53.8% |
| ROCE % | - | -168.1% | -49.3% | -47.9% | -81.5% | -379.2% | -400.7% | -152.7% | - | -24.1% | -50.3% | -60.4% | -1.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 61.16% | 2.64M | $30.06M |
| 2 | Nantahala Capital Management, LLC | 41.66% | 1.80M | $20.47M |
| 3 | State Street Corporation | 38.98% | 1.68M | $19.16M |
| 4 | Geode Capital Management, LLC | 35.71% | 1.54M | $17.55M |
| 5 | Shaw D.E. & Co., Inc. | 30.29% | 1.31M | $14.89M |
| 6 | Qube Research & Technologies Ltd | 28.77% | 1.24M | $14.14M |
| 7 | Morgan Stanley | 27.90% | 1.20M | $13.71M |
| 8 | Blackrock Inc. | - | 5.11M | $58.19M |
| 9 | FMR, LLC | - | 4.92M | $55.99M |
| 10 | Woodline Partners LP | - | 4.79M | $54.51M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ZVRA
Zevra Therapeutics, Inc. Estimates – NASDAQ:ZVRA - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE1Pa3hUNHFFelJIV3NUVWoxalZoQVMteVlLTUVXUzRZckNNR1BSbDFaM2ltaGNaN2VXdWtSeFcteG8wYWQzYzRMdnFKclh0ZE9kUE1kclNVWUtZaTRjcVRSZlVySVB6SFBKaVhOMWlPMjRublMzWUpUUw?oc=5" target="_blank">Zevra…
ZVRA May 2027 10.000 call (ZVRA270521C00010000) interactive stock chart - Yahoo Finance Australia
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBUMFlQaVhfaFFLODRIYlVOd1RBSFJUZFdiQ2MxN1QxV2JjSkdPOHdETl93bFkyMmh4VnZJUXRuMll6ODZMSWt4Wk5XbVdhYnBFZWZtVnkxcnh5dVh0SVpHQkdPSXg4Rm1FeTRrWnd3?oc=5" target="_blank">ZVRA May 2027 10.00…
ZVRA Nov 2026 5.000 call (ZVRA261120C00005000) interactive stock chart - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE1oZ0gxTnhDOUlKdE0waU94YW9rQlV0cHVfaDFSZ0FCSENDeVVZQlhqeUw1Um5XelRuWFo1RTZQN2lHT2pyZjVDNTRNeFIyQjgweTIyeG5rZmxXd1lxeGg1SGhHQkk3UHhqR1Y5LXBn?oc=5" target="_blank">ZVRA Nov 2026 5.000…
ZVRA May 2027 16.000 call (ZVRA270521C00016000) Stock Historical Prices & Data - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMicEFVX3lxTE1tMlZhQTItNng3eWlZRFUtZEFiLVJRM3JPYWdfNHI0N21EaVdreWFiQlFYdm1IQTVQVjFZNFZtVDdDZXVaYnhId1VhY0hpc20yeXVBcHJsME4wbm82dTV1WjJNU2ZjNUdFMVB1ckFfT08?oc=5" target="_blank">ZVRA May 2027 16…
ZVRA261120P00012000 Interactive Stock Chart | ZVRA Nov 2026 12.000 put Stock - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFBFcThmaEZrcGJRTFZ5Ym9pT3laZ2pFUzd1UXhQNEtrdEpMZ3JGbk95cm40eDZTWVZuUjdVZWphOXhGTk5rN01BeUFyenpkczJKVDkzRGlhZkRNZjRDNWZYXw?oc=5" target="_blank">ZVRA261120P00012000 Interactive Stock…
ZVRA Dec 2027 12.000 put (ZVRA271217P00012000) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTE5QVkRscWxyeDh2QU91ay1acDBaTVpaM2l1ak1fUDhWUnl0RTVWSUc1SkkwUTdFR3BCbFg1M3VIYTVUU0VPS01uV3dudVVvQjg0WWh3ZEtyNlFNcWQ5SF9lOGZsTkZQUQ?oc=5" target="_blank">ZVRA Dec 2027 12.000 put (ZVR…
ZVRA — Frequently Asked Questions
What is the current share price of Zevra Therapeutics, Inc. (ZVRA)?
As of 2026-10-23 16:27 PDT, Zevra Therapeutics, Inc. (ZVRA) trades at $9.81 on NasdaqGS. Its 52-week range is $7.23 to $14.75.
What is the market capitalisation of ZVRA?
Zevra Therapeutics, Inc. (ZVRA) has a market capitalisation of $582.55M on NasdaqGS.
What is the P/E ratio of ZVRA?
ZVRA trades at a trailing price-to-earnings (P/E) ratio of 10.55. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 3.17.
What is the return on equity (ROE) of ZVRA?
ZVRA has a return on equity (ROE) of 34.80%. Its return on capital employed (ROCE) is -1.72%.
Is ZVRA a good stock to buy?
This page provides a data-driven analysis of Zevra Therapeutics, Inc. (ZVRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.